Ledipasvir (formally labeled as GS-5885, GS5885, GS 5885)is an inhibitor of non-structural protein 5A of hepatitis C virus, most commonly used in combination with sofosbuvir for treatment in chronic hepatitis C genotype 1 patients. It inhibits an important viral phosphoprotein, NS5A, which is involved in viral replication, assembly and secretion.
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.
NS5A inhibitors in the treatment of hepatitis C.
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection.
Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451.
 E.J.Lawitz, et al, J. Hepatol., 2012, 57(1), pp 24-31.
 J.M.Pawlotsky, et al, J. Hepatol., 2013, 59(2), pp 375-385.
 N.Afdhal, et al, N. Engl. J. Med., 2014, 370, pp 1889-1898.